CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 52 enrolled
Drug / intervention
MYDAYIS +1 moredrug
Likely dose
MYDAYIS 12.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03945175
NCT03945175Phase 3Completed
CompareCT.gov

Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening

NYU Langone Health·interventional·Posted May 10, 2019·Updated Mar 8, 2024

In Brief

A Phase 3 clinical trial evaluating MYDAYIS and Placebo for Attention Deficit-Hyperactivity. Completed, enrolled 52 participants across 1 site.

Detailed Summary

Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder characterized by problems with sustaining attention, organization, planning, procrastination, daydreaming, restlessness, impulsivity and hyperactivity.This is an outpatient study for subjects between the ages of 18-60, who have an Attention deficit hyperactivity disorder (ADHD) diagnosis meeting all inclusion criteria and not meeting any of the exclusion criteria.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit-Hyperactivity
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 10, 2019
Enrollment StartJul 15, 2020
Primary CompletionMay 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.1 years ago

Interventions

MYDAYISdrug

MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.

Placebodrug

During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.